Table 4.

Outcomes in Clinical Trials of New Oral Anticoagulants

	Dabigatran (RE-LY)32,33	Rivaroxaban (ROCKET-AF)35	Apixaban (ARISTOLE)34
Stroke/systemic embolism	1.71% warfarin 1.54% dabigatran 110 mg 1.11% dabigatran 150 mga,b	2.4% warfarin 2.1% rivaroxaban	1.6% warfarin 1.27% apixabana,b
Safety
Major bleeding	3.57% warfarin 2.87% dabigatran 110 mga 3.32% dabigatran 150 mg	3.4% warfarin 3.6% rivaroxaban	3.09% warfarin 2.13% apixabana
Intracranial hemorrhage (%/year)	0.74% warfarin 0.23% dabigatran 110 mga 0.3% dabigatran 150 mga	0.7% warfarin 0.5% rivaroxabana	0.8% warfarin 0.33% apixaban
Myocardial Infarction	0.64% warfarin 0.82% dabigatran 110 mg 0.81% dabigatran 150 mg	1.1% warfarin 0.9% rivaroxaban	0.61% warfarin 0.53% apixaban

^aP < 0.05.

^bSuperiority.

Data from Connelly et al., Granger et al., and Patel et al.³²–³⁵